David B Hanna1, Chitra Ramaswamy2, Robert C Kaplan1,3, Jorge R Kizer4,5,6, Demetre Daskalakis7, Kathryn Anastos1,8, Sarah L Braunstein2. 1. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, New York, USA. 2. Bureau of Human Immunodeficiency Virus Prevention and Control, New York City Department of Health and Mental Hygiene, New York, USA. 3. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4. Cardiology Section, San Francisco Veterans Affairs Health Care System, University of California San Francisco, San Francisco, California, USA; and Departments of. 5. Medicine and, University of California San Francisco, San Francisco, California, USA. 6. Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA. 7. Division of Disease Control, New York City Department of Health and Mental Hygiene, New York. 8. Department of Medicine, Albert Einstein College of Medicine, New York, USA.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) may affect the risk of death due to cardiovascular disease (CVD) differently in men versus women. METHODS: We examined CVD mortality rates between 2007 and 2017 among all New York City residents living with HIV and aged 13+ by sex, using data from city HIV surveillance and vital statistics and the National Death Index. Residents without HIV were enumerated using modified US intercensal estimates. We determined associations of HIV status with CVD mortality by sex and neighborhood poverty, defined as the percent of residents living below the federal poverty level, after accounting for age, race/ethnicity, and year. RESULTS: There were 3234 CVD deaths reported among 147 915 New Yorkers living with HIV, with the proportion of deaths due to CVD increasing from 11% in 2007 to 22% in 2017. The age-standardized CVD mortality rate was 2.7/1000 person-years among both men and women with HIV. The relative rate of CVD mortality associated with HIV status was significantly higher among women (adjusted rate ratio [aRR] 1.7, 95% confidence interval [CI] 1.6-1.8) than men (aRR 1.2, 95% CI 1.1-1.3) overall, and within strata defined by neighborhood poverty. Sex differences in CVD mortality rates were the greatest when comparing individuals living with HIV and having detectable HIV RNA and CD4+ T-cell counts <500 cells/uL with individuals living without HIV. CONCLUSIONS: Among people with HIV, 1 in 5 deaths is now associated with CVD. HIV providers should recognize the CVD risk among women with HIV, and reinforce preventive measures (eg, smoking cessation, blood pressure control, lipid management) and viremic control among people living with HIV regardless of neighborhood poverty to reduce CVD mortality.Human immunodeficiency virus (HIV) increases cardiovascular disease mortality risks to a greater degree among women than men, even after accounting for neighborhood poverty. HIV providers should emphasize cardiovascular disease prevention (eg, smoking cessation, hypertension control, lipid management) and viremic control.
BACKGROUND: Human immunodeficiency virus (HIV) may affect the risk of death due to cardiovascular disease (CVD) differently in men versus women. METHODS: We examined CVD mortality rates between 2007 and 2017 among all New York City residents living with HIV and aged 13+ by sex, using data from city HIV surveillance and vital statistics and the National Death Index. Residents without HIV were enumerated using modified US intercensal estimates. We determined associations of HIV status with CVD mortality by sex and neighborhood poverty, defined as the percent of residents living below the federal poverty level, after accounting for age, race/ethnicity, and year. RESULTS: There were 3234 CVD deaths reported among 147 915 New Yorkers living with HIV, with the proportion of deaths due to CVD increasing from 11% in 2007 to 22% in 2017. The age-standardized CVD mortality rate was 2.7/1000 person-years among both men and women with HIV. The relative rate of CVD mortality associated with HIV status was significantly higher among women (adjusted rate ratio [aRR] 1.7, 95% confidence interval [CI] 1.6-1.8) than men (aRR 1.2, 95% CI 1.1-1.3) overall, and within strata defined by neighborhood poverty. Sex differences in CVD mortality rates were the greatest when comparing individuals living with HIV and having detectable HIV RNA and CD4+ T-cell counts <500 cells/uL with individuals living without HIV. CONCLUSIONS: Among people with HIV, 1 in 5 deaths is now associated with CVD. HIV providers should recognize the CVD risk among women with HIV, and reinforce preventive measures (eg, smoking cessation, blood pressure control, lipid management) and viremic control among people living with HIV regardless of neighborhood poverty to reduce CVD mortality.Human immunodeficiency virus (HIV) increases cardiovascular disease mortality risks to a greater degree among women than men, even after accounting for neighborhood poverty. HIV providers should emphasize cardiovascular disease prevention (eg, smoking cessation, hypertension control, lipid management) and viremic control.
Authors: Zian H Tseng; Eric A Secemsky; David Dowdy; Eric Vittinghoff; Brian Moyers; Joseph K Wong; Diane V Havlir; Priscilla Y Hsue Journal: J Am Coll Cardiol Date: 2012-05-22 Impact factor: 24.094
Authors: Daniel B Klein; Wendy A Leyden; Lanfang Xu; Chun R Chao; Michael A Horberg; William J Towner; Leo B Hurley; Julia L Marcus; Charles P Quesenberry; Michael J Silverberg Journal: Clin Infect Dis Date: 2015-01-16 Impact factor: 9.079
Authors: Robert C Kaplan; Lawrence A Kingsley; A Richey Sharrett; Xiuhong Li; Jason Lazar; Phyllis C Tien; Wendy J Mack; Mardge H Cohen; Lisa Jacobson; Stephen J Gange Journal: Clin Infect Dis Date: 2007-09-12 Impact factor: 9.079
Authors: Richard A Elion; Keri N Althoff; Jinbing Zhang; Richard D Moore; Stephen J Gange; Mari M Kitahata; Heidi M Crane; Daniel R Drozd; James H Stein; Marina B Klein; Joseph J Eron; Michael J Silverberg; William C Mathews; Amy C Justice; Timothy R Sterling; Charles S Rabkin; Angel M Mayor; Daniel B Klein; Michael A Horberg; Ronald J Bosch; Oghenowede Eyawo; Frank J Palella Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Angela M Thompson-Paul; Stanley C Wei; Christine L Mattson; McKaylee Robertson; Alfonso C Hernandez-Romieu; Tanvir K Bell; Jacek Skarbinski Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.889
Authors: Brandilyn A Peters; Jee-Young Moon; David B Hanna; Olaf Kutsch; Margaret Fischl; Caitlin A Moran; Adaora A Adimora; Stephen Gange; Nadia R Roan; Katherine G Michel; Michael Augenbraun; Anjali Sharma; Alan Landay; Seema Desai; Robert C Kaplan Journal: J Infect Dis Date: 2022-02-15 Impact factor: 7.759
Authors: Erik Ehinger; Yanal Ghosheh; Akula Bala Pramod; Juan Lin; David B Hanna; Karin Mueller; Christopher P Durant; Livia Baas; Qibin Qi; Tao Wang; Konrad Buscher; Kathryn Anastos; Jason M Lazar; Wendy J Mack; Phyllis C Tien; Mardge H Cohen; Igho Ofotokun; Stephen Gange; Sonya L Heath; Howard N Hodis; Russell P Tracy; Alan L Landay; Robert C Kaplan; Klaus Ley Journal: Cardiovasc Res Date: 2021-03-21 Impact factor: 13.081
Authors: Brandilyn A Peters; Xiaonan Xue; Lila A Sheira; Qibin Qi; Anjali Sharma; Nanette Santoro; Maria L Alcaide; Igho Ofotokun; Adaora A Adimora; Heather S McKay; Phyllis C Tien; Katherine G Michel; Deborah Gustafson; Bulent Turan; Alan L Landay; Robert C Kaplan; Sheri D Weiser Journal: J Infect Dis Date: 2022-01-18 Impact factor: 7.759